{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:42:33Z","timestamp":1790710953672,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1124\/molpharm.120.000042","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T23:30:14Z","timestamp":1600299014000},"page":"529-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism"],"prefix":"10.1016","volume":"98","author":[{"given":"Sonia J.","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet O.","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.120.000042_bib1","doi-asserted-by":"crossref","first-page":"20818","DOI":"10.1074\/jbc.RA117.000220","article-title":"b5 interactions with human cytochrome P450 enzymes","volume":"292","author":"Bart","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.120.000042_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/molpharm.120.000042_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jinorgbio.2009.12.017","article-title":"Cross-linking of human cytochrome P450 2B6 to NADPH-cytochrome P450 reductase: identification of a potential site of interaction","volume":"104","author":"Bumpus","year":"2010","journal-title":"J Inorg Biochem"},{"key":"10.1124\/molpharm.120.000042_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/molpharm.120.000042_bib5","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1107\/S0021889802016709","article-title":"An automated system to mount cryo-cooled protein crystals on a synchrotron beam line, using compact sample cassettes and a small-scale robot","volume":"35","author":"Cohen","year":"2002","journal-title":"J Appl Cryst"},{"key":"10.1124\/molpharm.120.000042_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00008571-199706000-00005","article-title":"The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase","volume":"7","author":"Crespi","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1124\/molpharm.120.000042_bib7","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jmb.2004.10.015","article-title":"Analysis of void volumes in proteins and application to stability of the p53 tumour suppressor protein","volume":"344","author":"Cuff","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1124\/molpharm.120.000042_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jpm8010001","article-title":"Pharmacogenomics of CYP2C9: functional and clinical considerations","volume":"8","author":"Daly","year":"2017","journal-title":"J Pers Med"},{"key":"10.1124\/molpharm.120.000042_bib9","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/molpharm.120.000042_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1107\/S0907444905036693","article-title":"Scaling and assessment of data quality","volume":"62","author":"Evans","year":"2006","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/molpharm.120.000042_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/molpharm.120.000042_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.tips.2016.05.006","article-title":"Recent structural insights into cytochrome P450 function","volume":"37","author":"Guengerich","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/molpharm.120.000042_bib13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","article-title":"Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes","volume":"3","author":"Ho","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/molpharm.120.000042_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00228-009-0707-7","article-title":"CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases","volume":"65","author":"Joy","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/molpharm.120.000042_bib15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1107\/S0907444993011333","article-title":"Detection, delineation, measurement and display of cavities in macromolecular structures","volume":"50","author":"Kleywegt","year":"1994","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/molpharm.120.000042_bib16","first-page":"E1203","article-title":"Steroid-based facial amphiphiles for stabilization and crystallization of membrane proteins","volume":"110","author":"Lee","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.120.000042_bib17","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1107\/S090744499900846X","article-title":"Integration of macromolecular diffraction data","volume":"55","author":"Leslie","year":"1999","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/molpharm.120.000042_bib18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0009-9236(95)90020-9","article-title":"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans","volume":"58","author":"Lo","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/molpharm.120.000042_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444907050172","article-title":"BALBES: a molecular-replacement pipeline","volume":"64","author":"Long","year":"2008","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/molpharm.120.000042_bib20","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1021\/acs.biochem.7b00795","article-title":"Structural basis of single-nucleotide polymorphisms in cytochrome P450 2C9","volume":"56","author":"Maekawa","year":"2017","journal-title":"Biochemistry"},{"key":"10.1124\/molpharm.120.000042_bib21","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1124\/dmd.109.027003","article-title":"Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects","volume":"37","author":"Maekawa","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/molpharm.120.000042_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1107\/S0909049502015170","article-title":"Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines","volume":"9","author":"McPhillips","year":"2002","journal-title":"J Synchrotron Radiat"},{"key":"10.1124\/molpharm.120.000042_bib23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/molpharm.120.000042_bib24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/molpharm.120.000042_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/tpj.2013.22","article-title":"Functional characterization of 32 CYP2C9 allelic variants","volume":"14","author":"Niinuma","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/molpharm.120.000042_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1006\/abio.1994.1357","article-title":"Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine","volume":"220","author":"Nourooz-Zadeh","year":"1994","journal-title":"Anal Biochem"},{"key":"10.1124\/molpharm.120.000042_bib27","series-title":"Structure, Mechanism, and Biochemistry","author":"Ortiz de Montellano","year":"2015"},{"key":"10.1124\/molpharm.120.000042_bib28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1107\/S0907444903008126","article-title":"A graphical user interface to the CCP4 program suite","volume":"59","author":"Potterton","year":"2003","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/molpharm.120.000042_bib29","doi-asserted-by":"crossref","first-page":"W368","DOI":"10.1093\/nar\/gky309","article-title":"MOLEonline: a web-based tool for analyzing channels, tunnels and pores (2018 update)","volume":"46","author":"Pravda","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/molpharm.120.000042_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.pharmtox.45.120403.095821","article-title":"Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics","volume":"45","author":"Rettie","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/molpharm.120.000042_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/tx00025a009","article-title":"Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions","volume":"5","author":"Rettie","year":"1992","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/molpharm.120.000042_bib32","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1158\/0008-5472.CAN-17-3977","article-title":"The cytochrome P450 slow metabolizers CYP2C9*2 and CYP2C9*3 directly regulate tumorigenesis via reduced epoxyeicosatrienoic acid production","volume":"78","author":"Sausville","year":"2018","journal-title":"Cancer Res"},{"key":"10.1124\/molpharm.120.000042_bib33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1124\/mol.115.102111","article-title":"Structure-function analysis of mammalian CYP2B enzymes using 7-substituted coumarin derivatives as probes: utility of crystal structures and molecular modeling in understanding xenobiotic metabolism","volume":"89","author":"Shah","year":"2016","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.120.000042_bib34","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1124\/mol.111.074427","article-title":"Structures of cytochrome P450 2B6 bound to 4-benzylpyridine and 4-(4-nitrobenzyl)pyridine: insight into inhibitor binding and rearrangement of active site side chains","volume":"80","author":"Shah","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.120.000042_bib35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2165\/00003088-200544080-00003","article-title":"Clinical pharmacokinetics of losartan","volume":"44","author":"Sica","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/molpharm.120.000042_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-62703-321-3_21","article-title":"Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database","volume":"987","author":"Sim","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1124\/molpharm.120.000042_bib37","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1107\/S0907444908030564","article-title":"New paradigm for macromolecular crystallography experiments at SSRL: automated crystal screening and remote data collection","volume":"64","author":"Soltis","year":"2008","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/molpharm.120.000042_bib38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00008571-199608000-00007","article-title":"The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism","volume":"6","author":"Sullivan-Klose","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1124\/molpharm.120.000042_bib39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1124\/molpharm.120.000042_bib40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FPC.0b013e3283349e84","article-title":"Cytochrome P450 2C9-CYP2C9","volume":"20","author":"Van Booven","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/molpharm.120.000042_bib41","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/mol.107.036178","article-title":"Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity","volume":"72","author":"Wei","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.120.000042_bib42","doi-asserted-by":"crossref","first-page":"10433","DOI":"10.1021\/ja403042k","article-title":"Structural and thermodynamic basis of (+)-\u03b1-pinene binding to human cytochrome P450 2B6","volume":"135","author":"Wilderman","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1124\/molpharm.120.000042_bib43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature01862","article-title":"Crystal structure of human cytochrome P450 2C9 with bound warfarin","volume":"424","author":"Williams","year":"2003","journal-title":"Nature"},{"key":"10.1124\/molpharm.120.000042_bib44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1124\/molpharm.120.000042_bib45","first-page":"1051","article-title":"Role of CYP2C9 polymorphism in losartan oxidation","volume":"29","author":"Yasar","year":"2001","journal-title":"Drug Metab Dispos"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24010708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24010708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.120.000042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:35:11Z","timestamp":1739961311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24010708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0026895X24010708"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.120.000042","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.120.000042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}